Posted by Michael Wonder on 09 Jan 2023
Opticyte earns FDA breakthrough device designation for the first cell O2 patient monitor for organ failure
9 January 2023 - Opticyte leverages proprietary machine learning to non-invasively assess organ dysfunction due to low cellular oxygenation in patients of all skin tones.
Opticyte announced today that its Cell O₂ Patient Monitor received breakthrough device designation from the US FDA for real time, continuous monitoring of patients at risk of organ failure.
